Prevalence of anxiety symptoms and associated factors at 2 months postpartum, results from a 2021 French national prospective cohort study
Abstract Background Postpartum anxiety (PPA) symptoms have harmful effects on child development and mother–infant interactions. Accordingly, in-depth knowledge of associated risk factors is crucial for prevention policies. This study aimed to estimate PPA symptom prevalence at 2 months and to identi...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2024-01-01
|
| Series: | European Psychiatry |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933824017991/type/journal_article |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841526442038394880 |
|---|---|
| author | Alexandra Doncarli Virginie Demiguel Camille Le Ray Catherine Deneux-Tharaux Elodie Lebreton Gisèle Apter Julie Boudet-Berquier Catherine Crenn-Hebert Marie-Noëlle Vacheron Nolwenn Regnault Sarah Tebeka Members of the ENP2021 Study Group |
| author_facet | Alexandra Doncarli Virginie Demiguel Camille Le Ray Catherine Deneux-Tharaux Elodie Lebreton Gisèle Apter Julie Boudet-Berquier Catherine Crenn-Hebert Marie-Noëlle Vacheron Nolwenn Regnault Sarah Tebeka Members of the ENP2021 Study Group |
| author_sort | Alexandra Doncarli |
| collection | DOAJ |
| description | Abstract
Background
Postpartum anxiety (PPA) symptoms have harmful effects on child development and mother–infant interactions. Accordingly, in-depth knowledge of associated risk factors is crucial for prevention policies. This study aimed to estimate PPA symptom prevalence at 2 months and to identify associated risk factors in a representative sample of all women who gave birth in France in 2021, and in two subgroups: women with no postpartum depression (PPD) symptoms, and those with no history of mental health care.
Methods
Among the 12,723 women included in the representative French national perinatal survey 2021ENP, 7,133 completed the Edinburgh Postnatal Depression Scale (EPDS) self-administered questionnaire – including three anxiety-specific items (EPDS-3A) – at 2 months postpartum. We estimated the adjusted prevalence ratios (aPR) of PPA symptoms using Poisson regression models with robust variance.
Results
PPA symptom prevalence at 2 months was 27.6% (95% CI [26.5–28.8]). Associated risk factors were: age ≤ 34 years (maximum aPR = 1.38 [1.22–1.58] obtained for persons aged 25–29 years vs. 35–39 years), poorer health literacy (1.15 [1.07–1.23]), a history of medical termination of pregnancy (1.32 [1.05–1.68]), psychological (1.31 [1.17–1.47]) or psychiatric (1.42 [1.24–1.63]) care history since adolescence, nulliparity (1.23 [1.12–1.35]), no weight gain or loss (1.29 [1.03–1.61] vs. 9–15 kg gain) or gain ≥23 kg (1.20 [1.00–1.43]) during pregnancy, ≥3 pregnancy-related emergency consultations (1.16 [1.03–1.31] vs. none), poor/good support during pregnancy, (1.16 [1.00–1.34] and 1.15 [1.05–1.26], respectively, vs. very good), sadness (1.52 [1.36–1.69]), anhedonia (1.48 [1.27–1.72]), or both (1.99 [1.79–2.21]) during pregnancy, not at all/not very satisfied with pain management during childbirth (1.16 [1.01–1.32] vs. quite/very satisfied). Similar risk factors were found in the ‘no PPD symptoms’ and ‘no history of mental health care’ subgroups.
Conclusions
Estimated PPA symptom prevalence at 2 months in our study sample was 27.6%. The risk factors we identified may guide future prevention policies.
|
| format | Article |
| id | doaj-art-99af6846abaa447c85ffd9ed662cd2c4 |
| institution | Kabale University |
| issn | 0924-9338 1778-3585 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj-art-99af6846abaa447c85ffd9ed662cd2c42025-01-16T21:50:36ZengCambridge University PressEuropean Psychiatry0924-93381778-35852024-01-016710.1192/j.eurpsy.2024.1799Prevalence of anxiety symptoms and associated factors at 2 months postpartum, results from a 2021 French national prospective cohort studyAlexandra Doncarli0https://orcid.org/0000-0002-0691-9136Virginie Demiguel1https://orcid.org/0000-0002-2677-6259Camille Le Ray2https://orcid.org/0000-0003-0891-1063Catherine Deneux-Tharaux3https://orcid.org/0000-0002-6561-3321Elodie Lebreton4https://orcid.org/0000-0003-2281-2942Gisèle Apter5https://orcid.org/0000-0001-5185-1479Julie Boudet-Berquier6https://orcid.org/0000-0002-2278-3697Catherine Crenn-Hebert7https://orcid.org/0000-0002-8175-188XMarie-Noëlle Vacheron8Nolwenn Regnault9https://orcid.org/0000-0002-0781-1450Sarah Tebeka10https://orcid.org/0000-0003-0269-4600Members of the ENP2021 Study GroupSanté publique France, the national public health agency, Saint-Maurice, FranceSanté publique France, the national public health agency, Saint-Maurice, FranceUniversité Paris Cité, Obstetrical Perinatal and Pediatric Epidemiology Research Team (EPOPé), CRESS U1153, INSERM, INRAE; Port Royal Maternity Unit, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, FHU Prema, Paris, FranceUniversité Paris Cité, Obstetrical Perinatal and Pediatric Epidemiology Research Team (EPOPé), CRESS U1153, INSERM, INRAE, Paris, FranceSanté publique France, the national public health agency, Saint-Maurice, FranceLe Havre Hospital, Perinatal and Child Psychiatry; Normandie University, Le Havre, FranceSanté publique France, the national public health agency, Saint-Maurice, FranceLouis-Mourier Hospital, Department of Gynecology and Obstetrics, Assistance Publique-Hôpitaux de Paris, Colombes;Regional Health Agency of Ile de France (ARS-IDF), Paris, FranceSainte Anne Hospital, GHU Paris Psychiatrie et Neurosciences, Consultation d’Information, de Conseils et d’Orientation des femmes suivies pour troubles psychiques, enceintes, ou avec désir d’enfant (CICO), Paris, FranceSanté publique France, the national public health agency, Saint-Maurice, FranceSanté publique France, the national public health agency, Saint-Maurice, FranceAbstract Background Postpartum anxiety (PPA) symptoms have harmful effects on child development and mother–infant interactions. Accordingly, in-depth knowledge of associated risk factors is crucial for prevention policies. This study aimed to estimate PPA symptom prevalence at 2 months and to identify associated risk factors in a representative sample of all women who gave birth in France in 2021, and in two subgroups: women with no postpartum depression (PPD) symptoms, and those with no history of mental health care. Methods Among the 12,723 women included in the representative French national perinatal survey 2021ENP, 7,133 completed the Edinburgh Postnatal Depression Scale (EPDS) self-administered questionnaire – including three anxiety-specific items (EPDS-3A) – at 2 months postpartum. We estimated the adjusted prevalence ratios (aPR) of PPA symptoms using Poisson regression models with robust variance. Results PPA symptom prevalence at 2 months was 27.6% (95% CI [26.5–28.8]). Associated risk factors were: age ≤ 34 years (maximum aPR = 1.38 [1.22–1.58] obtained for persons aged 25–29 years vs. 35–39 years), poorer health literacy (1.15 [1.07–1.23]), a history of medical termination of pregnancy (1.32 [1.05–1.68]), psychological (1.31 [1.17–1.47]) or psychiatric (1.42 [1.24–1.63]) care history since adolescence, nulliparity (1.23 [1.12–1.35]), no weight gain or loss (1.29 [1.03–1.61] vs. 9–15 kg gain) or gain ≥23 kg (1.20 [1.00–1.43]) during pregnancy, ≥3 pregnancy-related emergency consultations (1.16 [1.03–1.31] vs. none), poor/good support during pregnancy, (1.16 [1.00–1.34] and 1.15 [1.05–1.26], respectively, vs. very good), sadness (1.52 [1.36–1.69]), anhedonia (1.48 [1.27–1.72]), or both (1.99 [1.79–2.21]) during pregnancy, not at all/not very satisfied with pain management during childbirth (1.16 [1.01–1.32] vs. quite/very satisfied). Similar risk factors were found in the ‘no PPD symptoms’ and ‘no history of mental health care’ subgroups. Conclusions Estimated PPA symptom prevalence at 2 months in our study sample was 27.6%. The risk factors we identified may guide future prevention policies. https://www.cambridge.org/core/product/identifier/S0924933824017991/type/journal_articleMaternal anxietypostpartumdepressionrisk factors |
| spellingShingle | Alexandra Doncarli Virginie Demiguel Camille Le Ray Catherine Deneux-Tharaux Elodie Lebreton Gisèle Apter Julie Boudet-Berquier Catherine Crenn-Hebert Marie-Noëlle Vacheron Nolwenn Regnault Sarah Tebeka Members of the ENP2021 Study Group Prevalence of anxiety symptoms and associated factors at 2 months postpartum, results from a 2021 French national prospective cohort study European Psychiatry Maternal anxiety postpartum depression risk factors |
| title | Prevalence of anxiety symptoms and associated factors at 2 months postpartum, results from a 2021 French national prospective cohort study |
| title_full | Prevalence of anxiety symptoms and associated factors at 2 months postpartum, results from a 2021 French national prospective cohort study |
| title_fullStr | Prevalence of anxiety symptoms and associated factors at 2 months postpartum, results from a 2021 French national prospective cohort study |
| title_full_unstemmed | Prevalence of anxiety symptoms and associated factors at 2 months postpartum, results from a 2021 French national prospective cohort study |
| title_short | Prevalence of anxiety symptoms and associated factors at 2 months postpartum, results from a 2021 French national prospective cohort study |
| title_sort | prevalence of anxiety symptoms and associated factors at 2 months postpartum results from a 2021 french national prospective cohort study |
| topic | Maternal anxiety postpartum depression risk factors |
| url | https://www.cambridge.org/core/product/identifier/S0924933824017991/type/journal_article |
| work_keys_str_mv | AT alexandradoncarli prevalenceofanxietysymptomsandassociatedfactorsat2monthspostpartumresultsfroma2021frenchnationalprospectivecohortstudy AT virginiedemiguel prevalenceofanxietysymptomsandassociatedfactorsat2monthspostpartumresultsfroma2021frenchnationalprospectivecohortstudy AT camilleleray prevalenceofanxietysymptomsandassociatedfactorsat2monthspostpartumresultsfroma2021frenchnationalprospectivecohortstudy AT catherinedeneuxtharaux prevalenceofanxietysymptomsandassociatedfactorsat2monthspostpartumresultsfroma2021frenchnationalprospectivecohortstudy AT elodielebreton prevalenceofanxietysymptomsandassociatedfactorsat2monthspostpartumresultsfroma2021frenchnationalprospectivecohortstudy AT giseleapter prevalenceofanxietysymptomsandassociatedfactorsat2monthspostpartumresultsfroma2021frenchnationalprospectivecohortstudy AT julieboudetberquier prevalenceofanxietysymptomsandassociatedfactorsat2monthspostpartumresultsfroma2021frenchnationalprospectivecohortstudy AT catherinecrennhebert prevalenceofanxietysymptomsandassociatedfactorsat2monthspostpartumresultsfroma2021frenchnationalprospectivecohortstudy AT marienoellevacheron prevalenceofanxietysymptomsandassociatedfactorsat2monthspostpartumresultsfroma2021frenchnationalprospectivecohortstudy AT nolwennregnault prevalenceofanxietysymptomsandassociatedfactorsat2monthspostpartumresultsfroma2021frenchnationalprospectivecohortstudy AT sarahtebeka prevalenceofanxietysymptomsandassociatedfactorsat2monthspostpartumresultsfroma2021frenchnationalprospectivecohortstudy AT membersoftheenp2021studygroup prevalenceofanxietysymptomsandassociatedfactorsat2monthspostpartumresultsfroma2021frenchnationalprospectivecohortstudy |